| Drug General Information |
| Drug ID |
D0N1WU
|
| Former ID |
DAP000778
|
| Drug Name |
Etodolac
|
| Drug Type |
Small molecular drug
|
| Indication |
Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]
|
Approved |
[1],
[2]
|
|---|
| Therapeutic Class |
Analgesics
|
| Company |
Meda Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H21NO3
|
| InChIKey |
NNYBQONXHNTVIJ-UHFFFAOYSA-N
|
| CAS Number |
CAS 41340-25-4
|
| PubChem Compound ID |
|
| PubChem Substance ID |
9204, 143623, 224459, 855612, 5268437, 7847381, 7979205, 8149693, 8152106, 10321309, 11335322, 11360561, 11364138, 11366700, 11369262, 11372457, 11373819, 11377424, 11461533, 11466259, 11467379, 11485110, 11485958, 11489203, 11491244, 11492225, 11495058, 12012673, 14824710, 17405042, 24278407, 26612147, 26680024, 26747213, 26747214, 29222445, 46505184, 47885271, 47959585, 47959586, 48034967, 48110316, 48184861, 48259079, 48334348, 48413770, 49698757, 49857374, 50105240, 50105241
|
| SuperDrug ATC ID |
M01AB08
|
| SuperDrug CAS ID |
cas=041340254
|
| Target and Pathway |
| Target(s) |
Prostaglandin G/H synthase 2 |
Target Info |
Inhibitor |
[3],
[4]
|
|---|
|
BioCyc Pathway
|
Aspirin-triggered lipoxin biosynthesis
|
|
Aspirin triggered resolvin D biosynthesis
|
|
C20 prostanoid biosynthesis
|
|
Aspirin triggered resolvin E biosynthesis
|
|
KEGG Pathway
|
Arachidonic acid metabolism
|
|
Metabolic pathways
|
|
NF-kappa B signaling pathway
|
|
VEGF signaling pathway
|
|
TNF signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Serotonergic synapse
|
|
Ovarian steroidogenesis
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Leishmaniasis
|
|
Pathways in cancer
|
|
Chemical carcinogenesis
|
|
MicroRNAs in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TSH Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
IL5 Signaling Pathway
|
|
PANTHER Pathway
|
Endothelin signaling pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Toll receptor signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
S1P1 pathway
|
|
C-MYB transcription factor network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
PathWhiz Pathway
|
Arachidonic Acid Metabolism
|
|
WikiPathways
|
Prostaglandin Synthesis and Regulation
|
|
Arachidonic acid metabolism
|
|
Aryl Hydrocarbon Receptor
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Eicosanoid Synthesis
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074819. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7185). |
|---|
| REF 3 | Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol. 2001 Jul;8(7):S35-9. |
|---|
| REF 4 | Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. Epub 2007 Jul 2. |
|---|
